EU HTA Regulation: ‘Stepping Beyond’ JCAs May Be Needed For Very Rare Disease Drugs

 
• By Francesca Bruce
  
Future changes to the joint clinical assessment process could benefit treatments for very rare diseases. (Shutterstock)

More from Conferences

More from Rare Diseases